Goldman Sachs maintains buy on Ultragenyx, target at $78
Goldman Sachs reiterated its Buy rating on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares with a steady price target of $78.00. The firm's analyst highlighted Ultragenyx's fourth-quarter total ...
Ultragenyx reports Q4 EPS ($1.39), consensus ($1.27)
Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...
Year-end Report - January-December 2024
Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Year-end Report January-December 2024. The full report is available on the Company's website. “Stronger liquidity will ensure our ...
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...
Ultragenyx stock holds Buy rating, $140 target from Truist
Truist Securities maintained a positive outlook on Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), reiterating a Buy rating and a price target of $140. The firm's analyst highlighted the company's ...